本监测报告内容覆盖智能制造装备总体产业，包括智能测控装置、关键基础零部件、智能化高端装备和重大集成智能装备等智能制造装备的细分产业；以关键制造环节的智能化为核心，以端到端数据流为基础，和以网通互联为支撑。包括智能产品、智能生产、智能工厂、智能物流、各类智能机器人等。

NIPT was first discovered by Sequenom Inc., in 2010 when they launched the SensiGene Fetal RHD Genotyping laboratory-developed test to detect circulating cff-DNA from maternal blood. NIPT is rapidly commercializing due to the advancement of non-invasive technologies associated with it. The exponential growth of the NIPT market is supported by various factors, such as reimbursement policies, insurance coverage, high incidence rate of Down’s syndrome, no risk of miscarriage with NIPT, and shifting trend toward childbirth at advanced maternal age (35 years or above). However, low cost-effectiveness and inconsistent insurance coverage are hindering the market growth in some parts of the globe, mainly in the developing and under-developed nations of the world. Further, NIPT is also used for fetal sex determination and fetal rhesus D status determination in some parts of Europe. As of 2015, NIPT was offered in 60 countries throughout six continents.

With increasing evidence surfacing from the Human Microbiome Project, the coevolution of the hostmicrobiome superorganism and the unperturbed microbial component of the dyad has appeared to render sustainable host health. This coevolution has been proved by a consistently growing body of science to have a significant role in shaping evolving phenotypes in humans. The microbiota ecosystems develop, restricted to their epithelial niches by the host immune system, concomitantly with the host chronological development, providing early modulation of physiological host development and functions for nutrition, immunity, and resistance to pathogens at all ages. As a result of these findings, the human microbiome has often been dubbed as the “second genome”, attracting massive investment and research potential. Followed by globally relevant activities that have delved deeper into understanding the role of the microbiome on human health, the symbiosis between the human host and the microbiome, now deemed as the human holobiont, has emerged as the next frontier of embedding precision care into health regimens.

With the advancements in healthcare applications, such as companion diagnostics, biomarkers, and next-generation sequencing, the demand for precise drugs and tests has increased. This advancement has further enhanced the potential of precision medicine and the possibility of better outcome delivery. The global precision medicine market has been identified as one of the fastest emerging industries, owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an array of public companies. The acceptance of precision medicine as an approach is regarded as one of the most noteworthy changes in the healthcare industry because of its ability to provide improved diagnosis, prognosis, and patient/individual treatment processes. Despite recent breakthroughs and growing momentum of precision medicine, there are still significant challenges and barriers hampering or slowing down its global implementation and integration in medical practices.

Operating room integration (ORI) is designed to streamline the operating room by consolidating data, providing access to audio & video and controls for all devices at central command station, and allowing the surgeon to perform several tasks efficiently without the need to move around the operating room. In addition, the report studies the global operating room integration market that focuses on various applications such as urology, surgery, neuro, and others. The report includes a micro-level study of different regions adopting operating room integration for different end users. In addition, it discusses the potential opportunities for market players to enter the market. Moreover, it provides an in-depth market analysis of ORI, outlining current trends, key driving factors, and potential areas for product investments.

Rising focus on genomics over the past few years, coupled with the advancements in the field of molecular biology, has played an instrumental role in early diagnosis followed by the effective treatment of various diseases. The paradigm shift toward specific treatment along with the growing adoption of precision medicine has escalated the demand for genomic-based medicine by various end users. The incorporation of clinical biomarkers in breast cancer diagnostics aids in the identification of different biomarkers associated with the tumor grade and different cancer subtypes, which specifically reflects an individual’s health status accompanies and risk associated with breast cancer. The use of biomarker-based tests for identification of prognosis and recurrence of breast cancer has high predictive accuracy, minimally invasive, reproducible, and measurable, and is also widely accepted by the physicians and patients. In addition to this, breast cancer diagnostics based on clinical biomarkers have been extensively used for the evaluation of potential drug therapies. With the advancements in the field of biochemistry and medicine followed by omics, the clinical biomarkers appear to hold great potential for transforming medical practices into personalized medicine.

The umbilical cord blood stem cell market is a part of the stem cell market. Umbilical cord blood stem cells are collected from blood of umbilical cord and placenta after pregnancy. This blood has the potential to produce all essential components of blood, similar to stem cell derived from bone marrow and other sources. The market is segmented into three parts - storage service (public and private cord blood banks), therapeutics (Oncology, CVD, and diabetes), and application (stem cell transplant, and regenerative medicines).

Patient centric applications are tools that enable connection between practitioners, patients, and their families ensuring appropriate decision making for respective patients. These apps are developed considering the needs and preferences of patients to manage their health effectively. Thus, increasing the quality and efficiency of wellness management, and disease as well as treatment management. Rise in transition from institution centric to patient centric care integrating electronic communication at all levels has increased the adoption of patientcentric apps across the healthcare industry. A well-designed patient care application has the ability to enhance the quality and efficiency of healthcare by assisting patients in managing their health in a better manner.

2020 年国内新冠肺炎疫苗、四价流感疫苗等多品种获批上市。2020 年12月31 日北京所的新冠病毒灭活疫苗获附条件批准上市，成为第一支国产新冠病毒疫苗。此外，2020 年四价流感病毒疫苗、人用狂犬病疫苗（Vero细胞）等多个大品种获批上市。

结构性心脏病介入器械有望成为心血管器械中的创新主旋律领域。结构性心脏病主要包括先心病、瓣膜性疾病、心肌病等，伴随着介入手术的发展，该领域器械逐渐成为一个高增长、大体量、高价值的成长行业。2018年全球结构性心脏病器械市场规模90.4亿美元（其中2/3是介入器械），预计2023年行业有望达到150.4亿美元，复合增速10.8%。根据Frost&Sullivan数据，2018年国内心血管器械出厂市场规模约412亿元（+13%），我们预计其中结构性心脏病介入耗材5~10亿元左右，伴随相关创新产品上市和放量，对标全球市场结构， 预计2030年国内结构性心脏病介入器械有望达168亿元，具有10年10倍以上空间。基于行业空间大、增速快、创新潜力大、政策控费影响小、竞争格局好等5大特征，未来10年是瓣膜修复与置换以及左心耳封堵器将是极具投资潜力的创新器械赛道。